Hepatobiliary with CCK shortage of drug

Due to drug manufacturing shortages as reported by the drug vendor, Bracco Diagnostic on May 21, 2014 scheduling of outpatient Hepatobiliary studies, with cholecystokinin (CCK), will be discontinue. . The drug, Kinevac, has no known alternatives, prompting this action. 

The Centralized Scheduling Department has been requested to retain a list of patients requiring this test. Once supplies become available, they will coordinate the scheduling of these patients.

Should you have any questions, please feel free to contact me at 815-759-4080.

– John Heinrich – Director, Medical Imaging – CHS